A series of N-{2-oxo-2-[4-(1,3-benzothiazol-2-yl)piperazin-1-yl]}-(het) arenecarboxamides 4a - l, sulfonamide derivatives 8a - i as well as benzothiazole-containing N 1-(2-oxoethyl)-N 1-arylthioureas 9a - c have been synthesized. Compounds 4a - l and 9a were evaluated, in vitro, for their antiproliferative activity against a large panel of human tumor-derived cell lines. Compounds 4l and 9a were the most potent analogs in this series, showing remarkable effects on human splenic B-lymphoblastoid cells (WIL-2NS) and human acute B-lymphoblastic leukemia (CCRF-SB) cell lines (4l: CC 50 = 5.1 and 7.3 μM, respectively), and compound 5 against CCRF-SB cell lines with CC 50 = 2.3 μM. These compounds are leading candidates for further development. Compounds 6 - 7a - i were screened as inhibitors against HIV-1 and HIV-2, and no activity has been witnessed.

Synthesis, in vitro antiproliferative and anti-HIV activity of new derivatives of 2-Piperazino-1,3-benzo[d]thiazoles

LODDO, ROBERTA;
2010-01-01

Abstract

A series of N-{2-oxo-2-[4-(1,3-benzothiazol-2-yl)piperazin-1-yl]}-(het) arenecarboxamides 4a - l, sulfonamide derivatives 8a - i as well as benzothiazole-containing N 1-(2-oxoethyl)-N 1-arylthioureas 9a - c have been synthesized. Compounds 4a - l and 9a were evaluated, in vitro, for their antiproliferative activity against a large panel of human tumor-derived cell lines. Compounds 4l and 9a were the most potent analogs in this series, showing remarkable effects on human splenic B-lymphoblastoid cells (WIL-2NS) and human acute B-lymphoblastic leukemia (CCRF-SB) cell lines (4l: CC 50 = 5.1 and 7.3 μM, respectively), and compound 5 against CCRF-SB cell lines with CC 50 = 2.3 μM. These compounds are leading candidates for further development. Compounds 6 - 7a - i were screened as inhibitors against HIV-1 and HIV-2, and no activity has been witnessed.
2010
Amide; Anti-HIV activity; Antiproliferative activity
File in questo prodotto:
File Dimensione Formato  
Zeitschrift+Naturforschung[1].pdf

Solo gestori archivio

Tipologia: versione editoriale (VoR)
Dimensione 362.95 kB
Formato Adobe PDF
362.95 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11584/15783
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 9
social impact